Multinationals’ China Trial Strategies Shift As Industry Adapts
This article was originally published in PharmAsia News
The year of 2013 marked a new low for clinical trial approvals (CTAs) in China. A compliance crackdown that has brought caution to multinational firms in particular has added to fast-paced changes evident in the industry, says a clinical research insider with years of experience at multinational drug makers in China.
You may also be interested in...
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.
SinoVac’s rapid antibody response, CanSino’s easier logistics requirements - plus cost advantages - make Chinese developers optimistic about supplying the world with COVID vaccines.
The China bioventure sector is poised to set a record for initial public offerings and fundraising, but one therapeutic area is taking a surprise lead - immunology.